SHR6390
Phase 3Small molecule
SHR6390 is one of 30 small molecule programs targeting Breast Cancer. It is currently in Phase 3.
2
Indications
23
Total Trials
2
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1SHR6390
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer10 trials
Show 7 more trials
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04733417·35 enrolled
Impairment1 trial
Pancreatic Cancer1 trial
Hormone Receptor Positive1 trial
8 more indications
Gastric Cancer1 trial
Advanced1 trial
Adult1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR6390. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details